RecruitingNCT07109999

Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Sponsor

Xuanwu Hospital, Beijing

Enrollment

2,835 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

Alzheimer Disease

Summary

This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is building a research database to follow patients with early Alzheimer's disease over time, using advanced biomarker tests (blood, spinal fluid, or brain scans) to track how the disease progresses. The goal is to better understand which biological markers predict disease course and treatment response. **You may be eligible if...** - You are 40 years old or older - You are a patient at Xuanwu Hospital, Capital Medical University (China) - You have been diagnosed with mild cognitive impairment or probable Alzheimer's disease according to standard clinical criteria - You have a positive amyloid test — either from a brain PET scan or a spinal fluid test — confirming Alzheimer's-related changes in the brain - You are willing to provide informed consent **You may NOT be eligible if...** - You have severe physical or psychological conditions that prevent you from completing the assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNone-placebo

This study is an observational study, and no interventions will be implemented.

Locations(1)

Xuanwu Hospital of Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07109999

Related Trials

A Study of LY3439539 in Participants With Alzheimer's Disease

NCT075983707 locations

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229255 locations